| Document |
Document Title |
|
WO/2017/014285A1 |
A (meth)acryloyl compound represented by formula (A). (In formula (A): X is a single bond or a C1-60 2m-valent group; Z independently represents an oxygen atom, a sulfur atom, or being non-crosslinked; R1 independently represents a linea...
|
|
WO/2017/013299A1 |
The invention relates to a method for producing a concentrate of polymer proanthocyanidins with a concentration of more than 40%, characterised by the use of enzymatic treatments and by the absence of organic solvents and/or the extracti...
|
|
WO2017010381A1 |
Provided is an N-terminal labeling agent for a protein, comprising a compound represented by general formula (1) (where F is a fluorescent group, and R is an optionally substituted linker group having a linear soft segment formed from a ...
|
|
WO/2017/011210A1 |
The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-...
|
|
WO/2012/025587A9 |
The present invention is directed to a process for the manufacture of 2,3,5-trimethyl-hydro-p-benzoquinone comprising the following steps: a) hydrogenating 2,6-dimethyl-p-benzoquinone with hydrogen in the presence of a hydrogenation cata...
|
|
WO/2016/209753A1 |
Described herein are compounds, methods, and kits for short- and long-term tracking of cell proliferation, differentiation, and/or function. The compounds disclosed herein are coumarin- based cell-tracking reagents that fluoresce in the ...
|
|
WO/2016/208866A1 |
The present invention relates to a polymer compound used as a coloring resin composition for a color filter, the polymer compound including a structure represented by [chemical formula 1] or [chemical formula 2], and having excellent hea...
|
|
WO/2016/207913A1 |
The present disclosure provides a composition comprising brazilein which can be used as a fluorescent dye for enhanced visualization of nucleic acids such as DNA, and RNA. Also provided in the specification is a simple, time and cost eff...
|
|
WO/2016/205923A1 |
There is disclosed a process for forming an ingestible therapeutic plant source pill. In an embodiment, the process comprises: decarboxylating the plant source material to release carbon dioxide; testing potency of the plant source mater...
|
|
WO/2016/210392A1 |
N-substituted hydroxamic acids with carbon-based leaving groups as efficient HNO donors are disclosed. Pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions als...
|
|
WO/2016/201536A1 |
The present invention relates to a biotransformation method for transforming phenolic compounds from soy milk into bioactive isoflavones and equol, with a high yield and production volume, for use in the biotechnological field, mainly in...
|
|
WO/2016/204570A1 |
Provided in the present specification are a xanthene-based compound having a novel structure and a light-sensitive resin composition comprising same, and a light-sensitive material, a colour filter and a display element produced using same.
|
|
WO/2016/197463A1 |
Disclosed are a formononetin aliphatic ether derivative, and a preparation method and a pharmaceutical use thereof. Particularly disclosed are a formononetin aliphatic ether derivative of general formula (I), the preparation method there...
|
|
WO/2016/200934A1 |
Compounds, compositions and methods useful for treating cancer and neiirodegeneration are provided. The compounds comprise a mitochondria-targeting moiety linked to β-lapachone or a β-lapachone derivative.
|
|
WO/2016/191872A1 |
Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also...
|
|
WO/2016/193220A1 |
The present invention relates to a method for changing the pigmentation of a skin, a mucous membrane or hair with a compound of general formula (I), a cosmetic use of said compound of general formula (I), to cosmetic compositions compris...
|
|
WO/2016/192829A1 |
The present invention relates to feed media comprising deep eutectic solvents and/or ionic liquids.
|
|
WO/2016/192830A1 |
The present invention relates to cell culture media compositions comprising deep eutectic solvents and/or ionic liquids.
|
|
WO/2016/192631A1 |
The present invention provides an abietane-type diterpene compound having lipid-lowering activity, a method for preparing same, and use of same. Specifically, the compound has the structure shown in formula I. The definitions of the grou...
|
|
WO/2016/189877A1 |
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...
|
|
WO/2016/187722A1 |
Ocular compositions comprising a CB2 target agent and a cannabimimetic agent that is a non-selective cannabinoid receptor agent are useful in the treatment of ocular inflammation and ocular neuropathic pain. The CB2 target agent may be a...
|
|
WO/2016/188945A1 |
The present invention relates to the field of separating chiral isomers from each other. Particularly, it relates to the field of separating of chiral isomers of chromane or chromene compounds, particularly tocopherols, 3,4-dehydro-tocop...
|
|
WO/2016/190852A1 |
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of chromanyl compounds, and/or naturally or artificially occurring derivatives, analogues, stereoisomer...
|
|
WO/2016/183809A1 |
The present invention relates to a nebivolol synthesis method and intermediate compound thereof. Specifically, the present invention relates to a method for synthesizing nebivolol, intermediate compound thereof and method for preparing t...
|
|
WO/2016/183157A1 |
Isoflavonoids or pharmaceutically acceptable salts thereof or pharmaceutically acceptable compositions thereof for the treatment of prostate cancer or for the treatment or inhibition of prostate cancer metastasis in a patient in need the...
|
|
WO/2016/183185A1 |
Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): including stereoisomers, salts and tautomers thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, M, m and n are as defined he...
|
|
WO/2016/179645A1 |
The present disclosure relates to 4H-pyran compounds of formula (I) and their use in therapy, to compositions and agents comprising said compounds, to methods of treatment using said compounds, and their use in the manufacture of medicam...
|
|
WO/2016/183315A1 |
A glutathione-cleavable prodrug is provided herein, as well as methods for its use in treating cancer, including triple negative breast cancer. The prodrug can be cleaved by glutathione under physiological conditions to generate a biolog...
|
|
WO/2016/100576A9 |
The invention relates to methods of separating Trolox isomers (R)-Trolox and (S)-Trolox, comprising: (a) contacting a mixture of (R) and (S)-Trolox with a resolving agent selected from the group consisting of (1S,2S)-(+)-Pseudoephedrine,...
|
|
WO/2016/174226A1 |
The present invention relates to compounds of general formula (I), wherein R1-R8 take various meanings, pharmaceutical compositions containing them and their use in medicine, particularly for the treatment and/or prophylaxis of cancer.
|
|
WO/2016/166623A1 |
A system for collecting cannabis and the psychoactive component tetrahydrocannabinol from a sample of exhaled breath is disclosed. Single or multiple exhaled breaths are conditioned by removing contaminants, and regulating flow rate and/...
|
|
WO/2016/158169A1 |
The present invention is a compound represented by general formula (1).
|
|
WO/2016/158168A1 |
This resist composition contains one or more components selected from among compounds represented by a specified formula, and resins obtained using the compounds as monomers.
|
|
WO/2016/154705A1 |
The invention provides in part dhilirolide compounds for insect control, for such insects as Trichoplusia ni, and methods thereof. The compounds include compounds of Formula I.
|
|
WO/2016/159021A1 |
[Problem] To provide a novel compound. [Solution] A compound represented by formula (I) or formula (II), a salt thereof, or a solvate thereof. R1 represents a hydrogen atom or a halogen atom; each of R2-R4 represents a hydrogen atom, a h...
|
|
WO/2016/151484A1 |
This invention relates to new inhibitors of butyrylcholinesterase with general formulas I and II, where substituents are described in patent description. Compounds can be in the form of pure enantiomers or as racemic mixtures, or in the ...
|
|
WO/2016/153432A1 |
The present invention relates to substituted phenyl cinnamyl ketones of Formula (I) for use in therapy: wherein R1 to R11 are defined as described in the specification, or a pharmaceutically acceptable salt, tautomer(s), solvate or polym...
|
|
WO/2016/150025A1 |
A method for preparing high-content mixed tocopherols through lyotropic liquid crystal extraction and separation, comprising the following steps: dissolving vegetable oil deodorized distillate which is esterified or is subjected to fatty...
|
|
WO/2016/153167A1 |
The present invention relates to an isolation method for chrysoeriol using a planthopper. When using the method for isolating chrysoeriol from a rice plant inoculated with a planthopper according to the present invention, not only it is ...
|
|
WO/2016/154545A1 |
The present inventor has discovered how to adsorb a mitochondrially targeted compound (MTC) of general formula I on contact lenses and other matrices prior the application of lenses or other matrix on the eye surface. After such matrix i...
|
|
WO/2016/151295A1 |
The present invention relates to a process for producing an organic compound comprising an 18F atom, which process comprises treating a precursor organic compound comprising a –CY2X group with: (i) [18F] fluoride; and (ii) an activator...
|
|
WO/2016/147356A1 |
Provided are: an aromatic sulfonium salt compound that exhibits low corrosion with respect to a substrate, that has excellent photolithographic characteristics, and that is useful in a photoacid generator and a cationic polymerization ag...
|
|
WO/2016/149471A1 |
Novel fluorophores and their use as fluorescent tags for polymers used in wastewater treatment. The fluorophores are quaternary amine salts that can be used to synthesize fluorescent tagged polymers that are stable at varying pH, have si...
|
|
WO/2016/144637A1 |
A compound including an ester of tocopheryloxyacetic acid with an anticancer or antirestenotic agent selected from the group consisting of SN38, paclitaxel, camptothecin, 7-ethylcamptothecin, etoposide, fenretinide, and lestaurtinib. If ...
|
|
WO/2016/135346A1 |
The invention relates to cannabinoids, to the isolation and purification of same, as well as to obtaining these by means of centrifugal partition chromatography, a solvent being selected from the group consisting of cyclohexane, heptane,...
|
|
WO/2016/131098A1 |
ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in ...
|
|
WO/2016/127873A1 |
The present invention provides an isothiocyanate compound and an application thereof. The compound is an aryl substituted isothiocyanate compound that has a structure in the general formula I. The isothiocyanate compound in the present i...
|
|
WO/2016/129983A1 |
The present invention relates to novel N-acyl-diarysulfonamides acting as inhibitors of bacterial aminoacyl-tRNA synthetase. These can be used as medicines or as constituent of medicines for the treatment of bacterial infections.
|
|
WO/2016/130086A1 |
The present invention relates to the synthesis and characterization of an Abcg2 targeted fluorescence probe (compound of formula I), as well as live imaging of neural stem/progenitor cells (NSPCs) and isolation of live NSPCs using said p...
|
|
WO/2016/126423A2 |
Z is CR4R5, C=CR4R5 SiR4R5, GeR4R5 NR4a, PR4a, P(O)R4a, O, S, SO, SO2, Se; SeO, SeO2, Te, TeO, or TeO2; R1 - R3 are the same or different at each occurrence and are D, aryl, heteroaryl, alkyl, amino, silyl, germyl, deuterated aryl, deute...
|
